# A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

> **NCT03016312** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 759 (actual)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT03016312
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-10
- **Primary completion:** 2019-06-24
- **Final completion:** 2022-12-20
- **Target enrollment:** 759 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03016312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03016312, "A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03016312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*